Srinath Sanda
Associate Professor
+1 415 514-5234

What I Do

Pathogenesis of type 1 diabetes and cystic fibrosis related diabetes


Larson D, Patel P, Salapatek AM, Couroux P, Whitehouse D, Pina A, Johnson JL, Sever ML, Sanda S, Poyser J, Allio T, Scadding GW, Qin T, Shamji MH, Kwok WW, James EA, French D, Lelic A, Larché M, Altman MC, Togias A, Durham SR. Nasal Allergen Challenge and Environmental Exposure Chamber Challenge: A Randomized Trial Comparing Clinical and Biological Responses to Cat Allergen. J Allergy Clin Immunol. 2020 Mar 10.
Norris AW, Ode KL, Merjaneh L, Sanda S, Yi Y, Sun X, Engelhardt JF, Hull RL. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol. 2019 Feb 01.
Nagy N, Sunkari VG, Kaber G, Hasbun S, Lam DN, Speake C, Sanda S, McLaughlin TL, Wight TN, Long SR, Bollyky PL. Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control. Matrix Biol. 2019 07; 80:46-58.
Hull RL, Gibson RL, McNamara S, Deutsch GH, Fligner CL, Frevert CW, Ramsey BW, Sanda S. Islet Interleukin-1ß Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to ß-Cell Failure. Diabetes Care. 2018 04; 41(4):823-830.
Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol. 2017 Sep; 319:3-9.
Sanda S. Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes. 2018 03; 19(2):271-276.
Spindler MP, Ho AM, Tridgell D, McCulloch-Olson M, Gersuk V, Ni C, Greenbaum C, Sanda S. Acute hyperglycemia impairs IL-6 expression in humans. Immun Inflamm Dis. 2016 Mar; 4(1):91-7.
Durinovic-Belló I, Gersuk VH, Ni C, Wu R, Thorpe J, Jospe N, Sanda S, Greenbaum CJ, Nepom GT. Avidity-dependent programming of autoreactive T cells in T1D. PLoS One. 2014; 9(5):e98074.
Mauseth R, Hirsch IB, Bollyky J, Kircher R, Matheson D, Sanda S, Greenbaum C. Use of a "fuzzy logic" controller in a closed-loop artificial pancreas. Diabetes Technol Ther. 2013 Aug; 15(8):628-33.
Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 01; 381(9881):1905-15.
Yang J, James EA, Sanda S, Greenbaum C, Kwok WW. CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. Immunology. 2013 Mar; 138(3):269-79.
Chiu HK, Sanda S, Fechner PY, Pihoker C. Correlation of TSH with the risk of paediatric thyroid carcinoma. Clin Endocrinol (Oxf). 2012 Aug; 77(2):316-22.
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs ß-cell function. Diabetes. 2012 Sep; 61(9):2340-8.
Greenbaum CJ, Schatz DA, Haller MJ, Sanda S. Through the fog: recent clinical trials to preserve ß-cell function in type 1 diabetes. Diabetes. 2012 Jun; 61(6):1323-30.
Sanda S, Wei S, Rue T, Shilling H, Greenbaum C. A SNP in G6PC2 predicts insulin secretion in type 1 diabetes. Acta Diabetol. 2013 Jun; 50(3):459-62.
Kanter JE, Kramer F, Barnhart S, Averill MM, Vivekanandan-Giri A, Vickery T, Li LO, Becker L, Yuan W, Chait A, Braun KR, Potter-Perigo S, Sanda S, Wight TN, Pennathur S, Serhan CN, Heinecke JW, Coleman RA, Bornfeldt KE. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):E715-24.
Hondowicz BD, Schwedhelm KV, Kas A, Tasch MA, Rawlings C, Ramchurren N, McIntosh M, D'Amico LA, Sanda S, Standifer NE, Shendure J, Stone B. Discovery of T cell antigens by high-throughput screening of synthetic minigene libraries. PLoS One. 2012; 7(1):e29949.
Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, Luning Prak ET, Meyer-Bahlburg A, Sanda S, Greenbaum C, Rawlings DJ, Buckner JH. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol. 2012 Jan 01; 188(1):487-96.
Sanda S, Greenbaum CJ. Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363. Diabetes. 2011 Jun; 60(6):e17, author reply e18.
Sanda S, Bollyky J, Standifer N, Nepom G, Hamerman JA, Greenbaum C. Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clin Immunol. 2010 Aug; 136(2):170-3.
S. Alice Long, Karen Cerosaletti, Heather Shilling, Paul Bollyky, David Rawlings, Srinath Sanda, Jane Buckner. A T1D-associated Variant of PTPN2 Correlates with Decreased IL-2/IL-15 Responsiveness, Reduced FOXP3 Expression and Altered CD8 T Cell Differentiation. Clinical Immunology. 2010 Jan 1; 135:s118.
Brian Hondowicz, Katharine Schwedhelm, Arnold Kas, Michael Tasch, Nirasha Ramchurren, Nathan Standifer, Srinath Sanda, Crystal Rawlings, Jay Shendure, Brad Stone. High-throughput Screening for CD8+ T Cell Epitopes Targeted in Type 1 Diabetes. Clinical Immunology. 2010 Jan 1; 135:s19.
Srinath Sanda, Jenna Bollyky, Gerald Nepom, Jessica Hamerman, Carla Greenbaum. Reduced CD11b Integrin Expression with Short-term Administration of an IL-1R Antagonist in Type 1 Diabetes Patients. Clinical Immunology. 2010 Jan 1; 135:s106-s107.
Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes. 2010 Feb; 59(2):407-15.
Long SA, Walker MR, Rieck M, James E, Kwok WW, Sanda S, Pihoker C, Greenbaum C, Nepom GT, Buckner JH. Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur J Immunol. 2009 Feb; 39(2):612-20.
Ivana Durinovic-Bello, Rebecca Wu, Srinath Sanda, Gerald Nepom. F.69. Selection of Antigen Specific Autoreactive T Cells is Influenced by INS-VNTR Genotype. Clinical Immunology. 2009 Jan 1; 131:s112.
S. Alice Long, Paul Bollyky, Karen Cerosaletti, Heather Shilling, Catherine Pihoker, Srinath Sanda, Carla Greenbaum, Jane Buckner. OR.62. Impaired IL-2 Responsiveness and Treg Persistence in T1D is Revealed by Disease-Associated Variants in PTPN2. Clinical Immunology. 2009 Jan 1; 131:s26-s27.
Srinath Sanda, Jennifer Bollyky, Emily Burwell, Nathan Standifer, Gerald Nepom, Carla Greenbaum. T.128. Short-term Administration of Anakinra does not Appear to Affect Stimulated C-peptide Responses Acutely in Patients with Type 1 Diabetes. Clinical Immunology. 2009 Jan 1; 131:s89.
Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008 Nov 15; 181(10):7350-5.
Bollyky J, Sanda S, Greenbaum CJ. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention. Mt Sinai J Med. 2008 Aug; 75(4):385-97.
Sanda S, Schlingmann KP, Newfield RS. Autosomal dominant hypoparathyroidism with severe hypomagnesemia and hypocalcemia, successfully treated with recombinant PTH and continuous subcutaneous magnesium infusion. J Pediatr Endocrinol Metab. 2008 Apr; 21(4):385-91.
Sanda S, Roep BO, von Herrath M. Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol. 2008 May; 127(2):138-43.
Sanda S, Newfield RS. A child with pericardial effusion and cardiac tamponade due to previously unrecognized hypothyroidism. J Natl Med Assoc. 2007 Dec; 99(12):1411-3.
von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007 Dec; 7(12):988-94.
Srinath Sanda, Bart Roep, Matthias von Herrath. Reduced Foxp3 and Interleukin 10 Expression During the Partial Remission Phase of Type 1 Diabetes in Children. Clinical Immunology. 2007 Jan 1; 123:s16.